Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A synthetic small molecule belonging to the phenylpyrazole class. It features a pyrazolo[3,4-d]pyrimidine core substituted with a cyclobutyl group and a 3,4-dimethoxyphenyl moiety. This compound is primarily used as an experimental tool in biochemical research and has been studied for its inhibitory activity against several protein kinases. Notably, it acts as an inhibitor of tyrosine kinases such as ABL1 (Abelson murine leukemia viral oncogene homolog 1), EPHB4 (Ephrin type-B receptor 4), HCK (Hematopoietic cell kinase), mTOR (mechanistic target of rapamycin), PDGFRB (Platelet-derived growth factor receptor beta), PI3K isoforms (PIK3CA/PIK3CB/PIK3CD), PRKDC (DNA-dependent protein kinase catalytic subunit), and SRC family kinases. Its primary use is in preclinical or laboratory settings to probe kinase signaling pathways rather than clinical therapy[2][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine.